Precertification Required

Precertification is required for listed infertility injectable medications (eg, Cetrotide, ganirelix acetate, Follistim AQ, Gonal‑F, Menopur, Novarel, Pregnyl, Ovidrel, and chorionic gonadotropin). Contact Aetna Precertification at (866) 782-2779 or fax (860) 754-2515. Statement of Medical Necessity (SMN) forms are available on the Aetna Specialty Pharmacy Precertification forms page and may be required for review. Failure to obtain required precertification may result in claim denial.

• Precertification contact: (866) 782-2779; fax: (860) 754-2515
• SMN forms: Aetna Specialty Pharmacy Precertification forms

Prior Authorization May Be Required for IVF/Case‑Rate Services

Prior authorization (medical authorization) may be required for IVF and related case‑rate services and certain ART cycle codes; selection of case‑rate or cycle codes and authorization should be confirmed during benefit verification. For some plans ART/IVF is limited to persons meeting specific infertility or ART benefit criteria — check member’s benefit plan for ART coverage limits.

• IVF/case‑rate HCPCS examples: S4011, S4013–S4018, S4020–S4023, S4025–S4030, S4035, S4037, S4027, S4040, S4042
• Verify ART benefit and obtain medical authorization prior to ordering/administration

Prior Authorization for Experimental or Uncertain Procedures

Prior authorization is recommended for procedures considered investigational, experimental, or of uncertain clinical benefit (eg, in‑vitro maturation [IVM], many add‑on immunotherapies, certain forms of expanded PGD/PGS, some novel laboratory or surgical procedures). Experimental status may lead to denial; these services should generally be performed only in research settings or specialized centers and require prior review.

• IVM and cryopreservation of immature oocytes: considered experimental; restrict to specialized centers
• Add‑on procedures lacking high‑quality evidence (eg, many immunotherapies, unproven PGS/PGD approaches): prior review recommended

Prior Authorization Suggested for DuoStim and ERA

DuoStim (double stimulation) and Endometrial Receptivity Analysis (ERA) are emerging/limited‑evidence strategies. Prior authorization is suggested and use should be limited to the populations described in the literature (eg, DuoStim for poor prognosis patients or when expedited retrieval is essential; ERA primarily for research or selected clinical scenarios). Consider standard approaches first and document rationale when these options are pursued.

• DuoStim: reserve for poor prognosis patients or time‑sensitive fertility preservation; require documentation of prior standard approaches and rationale
• ERA: considered research use in many settings; document biopsy results and personalized ET timing when performed

UTx (Uterine Transplant) — Documentation and Prior Authorization Recommended

Uterine transplantation (UTx) is experimental, complex, and associated with substantial morbidity. Prior authorization is recommended before referral or scheduling. Candidates require multidisciplinary evaluation at experienced centers that meet programmatic and reporting requirements; document extensive pre‑operative testing, multidisciplinary consultations, and informed consent about risks and expected outcomes.

• UTx is experimental — prior authorization strongly recommended
• Document multidisciplinary consultations: gynecology, transplant surgery, psychology, immunology, anesthesiology, internal medicine, radiology
• Document center qualifications, case volume, outcomes reporting and patient counseling

Medication Limits and Benefit‑Check Prior to Authorization

Medication limits and benefit verification are required prior to authorization. Many plans exclude coverage for infertility injectables or sterilization reversals; some plans require pharmacy benefit review by Specialty Pharmacy Guideline Management. Verify the member’s benefit design for drug versus medical benefit coverage, plan‑specific exclusions, quantity limits, and brand‑step requirements (eg, Follistim AQ requires trial/failure of Gonal‑F per brand‑step policy).

• Check if injectables are covered under the pharmacy or medical benefit and whether Specialty Pharmacy review is required
• Dose/vial limits and standard limits are specified in the Appendix (eg, per‑28 day vial/cartridge limits)
• Brand‑step: Follistim AQ covered only after contraindication/intolerance/ineffective response to Gonal‑F

ICSI Coverage Conditions

ICSI is medically necessary in defined circumstances (eg, azoospermia/oligospermia, severe semen deficits, fertilization of frozen oocytes, iatrogenic infertility). If severe male factor infertility has been previously documented and then normalized after varicocelectomy, ICSI is considered not medically necessary. Document prior semen analyses and treatments.

• ICSI indications: azoospermia, severe sperm deficits, frozen oocyte fertilization, iatrogenic infertility due to cancer therapies
• If prior severe male‑factor resolved by varicocelectomy and semen normalizes, ICSI is not medically necessary

Operational Note — Authorization May Be Plan‑Specific

Some areas of this section describe prior authorization operational details or code listings only in the CPB code tables and appendices. Not every specific authorization requirement is enumerated here — always verify plan‑specific prior authorization rules during benefit check.

• When authorization requirements are not specified in the CPB, use benefit verification tools or contact Aetna for plan‑specific rules
• CPBs are a guide and do not replace plan contract language

Plan Exclusions, Coding‑Based Denial Risk, and Not‑Covered Codes

Plan exclusions and coding can trigger denials. Certain CPT/HCPCS/ICD‑10 codes are explicitly listed as not covered or limited for indications in this bulletin. Use correct diagnosis and procedure coding; avoid codes listed as not covered for CPB indications to reduce denial risk.

• Review CPB code lists for not‑covered codes and ICD‑10 exclusions
• Examples of HCPCS/CPT code groups and HCPCS storage/monitoring codes: S4027, S4040, S4042
• Coding errors or use of excluded ICD‑10 codes may lead to denial

IVM Considered Investigational — Prior Authorization/Research Setting

In‑vitro maturation (IVM) and cryopreservation of immature oocytes are considered investigational/experimental. These procedures should only be performed in specialized centers under research protocols and will generally require prior authorization and informed‑consent documentation.

• IVM: experimental — limit to specialized centers and research settings
• Document patient counseling regarding lower implantation/pregnancy rates compared with standard IVF

Contraindications May Preclude Coverage — Document FDA Label Considerations

Contraindications and FDA boxed warnings for reproductive drugs must be checked and documented prior to prescribing. FDA‑label contraindications (eg, hypersensitivity, primary gonadal failure, tumors, pregnancy when applicable) may preclude coverage or use and should be addressed in the medical record submitted for authorization.

• Review FDA contraindications/warnings for follitropins, menotropins, hCG preparations prior to administration
• Document clinical rationale when dispensing agents with label warnings and monitor for OHSS and other listed risks

DuoStim — Restricted Use and Prior Authorization Considerations

DuoStim should be considered primarily for poor‑prognosis patients or when time is critical. It is a later‑line or expedited option after standard stimulation cycles have been tried or when rapid fertility preservation is needed; prior authorization and clear documentation of prior treatments and rationale are recommended.

• DuoStim: apply only to poor prognosis patients or time‑sensitive cases; freeze‑all mandatory and require documentation of prior standard approaches
• No RCTs or cost‑effectiveness data are yet definitive — document shared decision making

ERA — Research Use Recommended; Documentation Required

ERA testing remains of uncertain routine benefit; many sources recommend use primarily in research or select clinical contexts. When ERA is performed, submit ERA biopsy reports and documentation of personalized embryo transfer timing and rationale with authorization requests.

• ERA documentation elements to include: biopsy result, receptive/non‑receptive result, personalized ET timing, indication (eg, recurrent implantation failure)
• Routine use of ERA in unselected patients is not broadly supported — consider research protocol or select indications

CFTR Testing and Counseling — Documentation Required

For congenital bilateral absence of the vas deferens (CBAVD) and related scenarios, CFTR genetic testing and counseling for the patient and partner should be documented when indicated. Semen fructose and other diagnostic tests and counseling should also be recorded.

• Document CFTR testing for man with CBAVD and testing/counseling of partner
• Record semen fructose and low volume/absent vas deferens findings and genetic counseling notes

Experimental Status May Trigger Denial — Prior Authorization and Documentation Recommended

Experimental procedures (eg, many add‑ons, UTx, IVM, novel genetic tests without established clinical utility) may lead to denial when billed outside approved research protocols or without prior authorization. Clearly document indication, prior treatments, and why approved alternatives are unsuitable.

• Experimental status of UTx and other procedures often triggers denials without prior authorization and documentation
• When pursuing experimental therapies, include evidence summary, informed consent, and justification for clinical use

High Likelihood of COH‑IUI Futility with Specific Day‑3 Hormone Profile

Patients with specific Day‑3 hormonal profiles (FSH 10–15 mIU/ml and E2 ≥ 40 pg/ml) have a high likelihood of COH‑IUI futility. Document Day‑3 FSH and E2 when considering COH‑IUI and consider proceeding to IVF when these markers predict poor response to COH‑IUI.

• Day‑3 FSH 10–15 mIU/ml and E2 ≥ 40 pg/ml: specificity and PPV for no live‑birth with COH‑IUI were high in cited trials
• Document hormonal test dates and values (FSH/E2)

Documentation for Storage and Monitoring Services (HCPCS Coding)

Documentation for storage and monitoring services (eg, storage of previously frozen embryos, per‑30 day embryo storage monitoring) should use appropriate HCPCS codes (eg, S4027, S4040, S4042) and include dates, consent for storage, and monitoring plan.

• Use HCPCS codes S4027, S4040, S4042 for embryo storage/monitoring and include storage start/end dates and consent forms
• Include monitoring documentation and inventory of cryopreserved specimens

Ovarian Responsiveness Documentation Required

Ovarian responsiveness must be documented prior to ovarian stimulation: obtain an unmedicated day‑3 FSH within 12 months for age ≤35 or within 6 months for age >35. In women >40, any single FSH >19 mIU/mL indicates ovarian insufficiency. In women <40, an unmedicated day‑3 FSH <19 mIU/mL demonstrates capacity to respond.

• Unmedicated day‑3 FSH timing: ≤35 years — within prior 12 months; >35 years — within prior 6 months
• Document FSH values and dates in authorization package

Ovarian Cyst Aspiration — Documentation of Rationale Required

Ovarian cyst aspiration prior to stimulation lacks conclusive benefit. If performed, document clinical rationale, cyst characteristics, and why conservative management was not chosen; be aware evidence does not support routine aspiration to improve live‑birth or cycle outcomes.

• Document cyst size, ultrasound characteristics, rationale for aspiration, informed consent, and anesthesia/surgical notes when applicable

Indication Documentation for Drugs and Procedures

Indication documentation is required for infertility medications and procedures. For drug therapies, document FDA‑approved indication, prior treatments, contraindications or intolerances to alternatives, and clinical rationale for the selected agent.

• Include prior therapy trials and response, FDA‑label indication for the drug, and any contraindications to alternatives in the medical record submitted for authorization

ERA — Required Documentation Elements

ERA documentation elements: include the endometrial biopsy report, ERA receptive/non‑receptive result, timing recommendations for personalized embryo transfer (pET), and clinical indication (eg, recurrent implantation failure). Submit these with authorization requests.

• ERA report, date of biopsy, receptive vs non‑receptive classification, recommended pET timing, and indication for testing

CFTR Testing — Documentation Required

CFTR testing documentation: when indicated (eg, CBAVD or low semen volume with absent vas), document CFTR testing results for the patient and partner, counseling provided, and any genetic counseling referrals.

• Record CFTR test date, method, results, partner testing status, and documented counseling/referral notes

Testing and Counseling Documentation for Male Infertility

Testing and counseling documentation for male infertility should include semen analysis results (use WHO reference values), semen fructose when vas absence suspected, counseling about genetic risks, and documentation of follow‑up plans.

• Semen analysis should report WHO reference parameters (pH, concentration, morphology, volume, motility, total sperm number, vitality)
• Document counseling and genetic testing when indicated (eg, CBAVD)

Multidisciplinary Evaluation Documentation for Complex Interventions

Multidisciplinary evaluation documentation is required for complex procedures (eg, UTx) — include consultations from gynecology, transplant surgery, psychology, immunology, anesthesiology, internal medicine, radiology, and any other specialty involved. Document testing, psychosocial evaluation, and informed consent.

• Include multidisciplinary consult notes, testing results, center capabilities, and documented informed consent in authorization requests for complex interventions

Cycle Monitoring and Medication Documentation

Cycle monitoring and medication documentation: record serial ultrasounds, serum hormone values, medication types/doses/dates, response to stimulation, and any adverse events. Appendix specifies medically necessary counts of monitoring tests per cycle — use that guidance when documenting.

• Document transvaginal ultrasound counts per cycle, estradiol/FSH/LH/progesterone measurements as applicable, medication name/dose/lot and administration dates
• Follow Appendix laboratory and gonadotropin vial management limits when requesting authorization

Semen Analysis — WHO Parameters and Repeat Testing

Semen analysis reporting should use WHO reference values and include key parameters (pH, concentration, morphology, volume, motility, total sperm number, vitality). Repeat abnormal semen analyses on at least 2 occasions ≥2 weeks apart when defining mild or severe male‑factor infertility.

• Repeat abnormal sperm parameters on 2 separate occasions at least 2 weeks apart to define severity
• Severe deficits: <10 million TMS unwashed or <3 million TMS washed; severe morphology <4% (Kruger strict)

Bibliography and References

This section contains references and bibliographic material. Providers must consult the cited clinical literature and practice guidelines when preparing authorization requests or when considering emerging/experimental procedures.

• Refer to CPB references and cited trials/guidelines when needed

Provider Documentation Note and Coverage Disclaimer

Provider documentation note: CPBs are a partial description of plan benefits and do not replace plan contracts. Providers should verify member benefits, prior authorization requirements, and plan exclusions; document all clinical findings and rationale submitted for review.

• Clinical Policy Bulletins do not guarantee coverage — verify contract/benefit details before proceeding
• Include complete documentation to support medical necessity determinations